论文部分内容阅读
Background:The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody(ANCA)-associated vasculitis.Methods:In this randomized,controlled trial,we assigned patients with ANCA-associated vasculitis in a 1:1